Penumbra Reports Strong Q4 and Full-Year 2025 Growth Despite China Headwinds
Event summary
- Q4 2025 revenue of $383.0M–$384.8M, up ~21.4%–22.0% YoY (ex-China: ~23.2%–23.8%)
- Full-year 2025 revenue of $1.40B–$1.40B+, up ~17.3%–17.5% YoY (ex-China: ~24.7%–24.9%)
- Q4 gross margin of 67.9%–68.1%; full-year at 67.1%
- Operating income of $56.9M–$60.4M in Q4 (margin: 14.8%–15.7%); full-year at $186.9M–$190.4M (margin: 13.3%–13.6%)
The big picture
Penumbra's strong 2025 performance highlights its leadership in thrombectomy solutions, but China's underperformance raises strategic questions about regional diversification. The company's ability to balance innovation with operational efficiency will be critical as it competes in a consolidating medical-device sector.
What we're watching
- China Market Recovery
- Whether Penumbra can stabilize or reverse China-related revenue declines amid broader regional challenges.
- Margin Sustainability
- How the company maintains gross margins near 68% while scaling operations globally.
- Innovation Pipeline
- The pace at which Penumbra advances its CAVT and other clot-removal technologies to sustain growth.
Related topics